Amphastar Pharmaceuticals (NASDAQ:AMPH) Director Richard Prins Sells 7,973 Shares

Posted by on Aug 13th, 2026

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Free Report) Director Richard Prins sold 7,973 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $20.30, for a total value of $161,851.90. Following the sale, the director owned 29,625 shares of the company’s stock, valued at approximately $601,387.50. This trade represents a 21.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Amphastar Pharmaceuticals Trading Down 2.2%

NASDAQ AMPH opened at $19.98 on Thursday. The company has a current ratio of 2.40, a quick ratio of 1.71 and a debt-to-equity ratio of 0.79. The stock has a market cap of $849.95 million, a PE ratio of 11.82, a PEG ratio of 4.31 and a beta of 0.89. The company’s 50-day moving average price is $19.78 and its 200-day moving average price is $21.23. Amphastar Pharmaceuticals, Inc. has a 12 month low of $16.65 and a 12 month high of $31.26.

Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.29. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.98%. The business had revenue of $183.90 million for the quarter, compared to analyst estimates of $179.92 million. Equities research analysts forecast that Amphastar Pharmaceuticals, Inc. will post 2.25 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on AMPH shares. Barclays reduced their price objective on Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating on the stock in a report on Wednesday, June 3rd. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Friday, May 8th. Weiss Ratings reissued a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, July 8th. Zacks Research upgraded Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 21st. Finally, Wall Street Zen upgraded Amphastar Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 8th. Six research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and an average price target of $22.00.

View Our Latest Stock Analysis on AMPH

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Quarry LP bought a new position in Amphastar Pharmaceuticals in the third quarter worth approximately $32,000. Farther Finance Advisors LLC boosted its position in Amphastar Pharmaceuticals by 46.3% during the 4th quarter. Farther Finance Advisors LLC now owns 1,381 shares of the company’s stock valued at $37,000 after acquiring an additional 437 shares in the last quarter. Quantbot Technologies LP bought a new stake in Amphastar Pharmaceuticals during the 2nd quarter valued at $39,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Amphastar Pharmaceuticals by 24.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,233 shares of the company’s stock valued at $60,000 after acquiring an additional 435 shares during the period. Finally, TD Private Client Wealth LLC grew its stake in Amphastar Pharmaceuticals by 410.1% in the fourth quarter. TD Private Client Wealth LLC now owns 2,418 shares of the company’s stock valued at $65,000 after purchasing an additional 1,944 shares during the last quarter. 65.09% of the stock is currently owned by institutional investors.

About Amphastar Pharmaceuticals

(Get Free Report)

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.

Featured Stories

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.